Research programme: anti-CMV therapy - Kemin Pharma
Alternative Names: KPE00001015; KPE00001116; KPE1015; KPE1116Latest Information Update: 23 Sep 2008
At a glance
- Originator Kemin Pharma
- Class Antivirals; Carbohydrates
- Mechanism of Action Cytomegalovirus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 23 Sep 2008 Discontinued - Preclinical for Cytomegalovirus infections in Belgium (unspecified route)
- 17 Mar 2008 Preclinical development is ongoing
- 13 Jan 2005 Lead compounds from this programme are available for licensing worldwide (http://www.kemin.com)